JPS6354690B2 - - Google Patents
Info
- Publication number
- JPS6354690B2 JPS6354690B2 JP61184973A JP18497386A JPS6354690B2 JP S6354690 B2 JPS6354690 B2 JP S6354690B2 JP 61184973 A JP61184973 A JP 61184973A JP 18497386 A JP18497386 A JP 18497386A JP S6354690 B2 JPS6354690 B2 JP S6354690B2
- Authority
- JP
- Japan
- Prior art keywords
- coenzyme
- heart
- agent according
- muscle metabolism
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 44
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 28
- 210000002216 heart Anatomy 0.000 claims description 11
- 210000003205 muscle Anatomy 0.000 claims description 11
- 230000004060 metabolic process Effects 0.000 claims description 8
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000005515 coenzyme Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940035936 ubiquinone Drugs 0.000 claims description 4
- 206010002660 Anoxia Diseases 0.000 claims description 3
- 241000976983 Anoxia Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000007953 anoxia Effects 0.000 claims description 3
- 230000003387 muscular Effects 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 229960003624 creatine Drugs 0.000 claims description 2
- 239000006046 creatine Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 2
- 239000003708 ampul Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000006371 metabolic abnormality Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013130 cardiovascular surgery Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000003540 papillary muscle Anatomy 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000000518 sarcolemma Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH3362/85A CH666183A5 (it) | 1985-08-06 | 1985-08-06 | Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare. |
| CH3362/85-1 | 1985-08-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6253924A JPS6253924A (ja) | 1987-03-09 |
| JPS6354690B2 true JPS6354690B2 (pl) | 1988-10-28 |
Family
ID=4254335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61184973A Granted JPS6253924A (ja) | 1985-08-06 | 1986-08-05 | 心臓および筋代謝保護剤 |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS6253924A (pl) |
| BE (1) | BE905210A (pl) |
| CH (1) | CH666183A5 (pl) |
| DE (1) | DE3625433A1 (pl) |
| FR (1) | FR2586352B1 (pl) |
| GB (1) | GB2178661B (pl) |
| IT (1) | IT1213319B (pl) |
| NL (1) | NL8601979A (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19537494C2 (de) * | 1995-09-25 | 1997-10-02 | Desitin Arzneimittel Gmbh | Kreatin zum Schutz von neuralem Gewebe |
| EP1407782A4 (en) * | 2001-06-28 | 2004-10-20 | Takeda Chemical Industries Ltd | DRUGS FOR THE PREVENTION / TREATMENT OF FUNCTIONAL ORGAN DISORDERS AND ORGAN DYSFUNCTION |
| DE202023001978U1 (de) | 2023-09-20 | 2023-09-29 | Penta Phi Eg | Formulierung umfassend Coenzym Q10 und Kreatin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH655005A5 (it) * | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. |
-
1985
- 1985-08-06 CH CH3362/85A patent/CH666183A5/it not_active IP Right Cessation
-
1986
- 1986-07-28 DE DE19863625433 patent/DE3625433A1/de active Granted
- 1986-07-30 GB GB8618589A patent/GB2178661B/en not_active Expired
- 1986-08-01 NL NL8601979A patent/NL8601979A/nl not_active Application Discontinuation
- 1986-08-01 IT IT8621394A patent/IT1213319B/it active
- 1986-08-04 BE BE2/61025A patent/BE905210A/nl not_active IP Right Cessation
- 1986-08-05 JP JP61184973A patent/JPS6253924A/ja active Granted
- 1986-08-06 FR FR868611375A patent/FR2586352B1/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2586352A1 (fr) | 1987-02-27 |
| FR2586352B1 (fr) | 1992-05-29 |
| IT1213319B (it) | 1989-12-20 |
| GB2178661A (en) | 1987-02-18 |
| IT8621394A0 (it) | 1986-08-01 |
| GB8618589D0 (en) | 1986-09-10 |
| GB2178661B (en) | 1989-08-31 |
| CH666183A5 (it) | 1988-07-15 |
| JPS6253924A (ja) | 1987-03-09 |
| BE905210A (nl) | 1986-12-01 |
| NL8601979A (nl) | 1987-03-02 |
| DE3625433A1 (de) | 1987-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3855120T2 (de) | The use of AICA riboside or AICA ribotide for the preparation of a medicament against heart attack or stroke in patients with atherosclerosis | |
| Fazekas et al. | Magnesium and the heart: antiarrhythmic therapy with magnesium | |
| EP0786993B1 (en) | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and their use in the treatment of metabolic and cardiovascular disorders | |
| JP2010510973A (ja) | 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用 | |
| AU782367B2 (en) | Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose | |
| JP3622985B2 (ja) | マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法 | |
| EP0199117A2 (en) | New therapeutical use of phosphocreatine | |
| JPS6354690B2 (pl) | ||
| US20050182136A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction | |
| US6410601B2 (en) | Histochrome and its therapeutic use in acute myocardial infarction and ischemic heart disease | |
| JPH0142246B2 (pl) | ||
| EP0530220B1 (en) | Pharmaceutical composition | |
| KR0136787B1 (ko) | 심장질환 치료에 쓰이는 프로파페논과 퀴니딘의 지속성 조성물 | |
| RU2096034C1 (ru) | Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием | |
| JPH0380771B2 (pl) | ||
| US20100016244A1 (en) | D-glucopyranose 1-[3,5-bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and use thereof | |
| EP0140958B1 (en) | Oncolytic drug combinations | |
| CA2083609C (en) | Preventive or therapeutic agent for ischemia-reperfusion tissue injury, arrhythmia and lung injury caused by active oxygens and free radicals | |
| JPH0526766B2 (pl) | ||
| Mittra | Use of potassium, glucose and insulin in the treatment of myocardial infarction | |
| RU2292885C2 (ru) | Антиаритмическое лекарственное средство "тиодарон" | |
| RU2045961C1 (ru) | Способ проведения коронарографии в эксперименте | |
| RU2627458C1 (ru) | Способ коррекции процессов перекисного окисления липидов у больных острым инфарктом миокарда | |
| CA2193838A1 (en) | Disease preventive/remedy | |
| RU2148999C1 (ru) | Применение этимизола в качестве антиаритмического средства для предупреждения желудочковой экстрасистолии у больных ибс |